Norinchukin Bank The increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 116,793 shares of the biopharmaceutical company’s stock after buying an additional 5,712 shares during the period. Norinchukin Bank The’s holdings in Gilead Sciences were worth $7,548,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently modified their holdings of GILD. Barrett Asset Management LLC grew its holdings in shares of Gilead Sciences by 333.0% during the fourth quarter. Barrett Asset Management LLC now owns 433 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 333 shares in the last quarter. Tortoise Investment Management LLC increased its holdings in shares of Gilead Sciences by 81.6% during the 4th quarter. Tortoise Investment Management LLC now owns 445 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 200 shares during the last quarter. Graves Light Private Wealth Management Inc. purchased a new position in shares of Gilead Sciences in the 4th quarter worth about $27,000. Elkhorn Partners Limited Partnership purchased a new stake in shares of Gilead Sciences during the 4th quarter worth about $29,000. Finally, Rockbridge Investment Management LCC lifted its position in Gilead Sciences by 236.5% during the fourth quarter. Rockbridge Investment Management LCC now owns 535 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 376 shares in the last quarter. 77.18% of the stock is owned by institutional investors.
In related news, Director Richard James Whitley sold 20,282 shares of the firm’s stock in a transaction that occurred on Monday, May 3rd. The shares were sold at an average price of $64.57, for a total transaction of $1,309,608.74. Following the transaction, the director now owns 51,404 shares of the company’s stock, valued at $3,319,156.28. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.12% of the company’s stock.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 29th. The biopharmaceutical company reported $2.08 EPS for the quarter, beating the Zacks’ consensus estimate of $2.06 by $0.02. The firm had revenue of $6.42 billion for the quarter, compared to the consensus estimate of $6.78 billion. Gilead Sciences had a net margin of 1.18% and a return on equity of 51.91%. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.07 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 29th. Shareholders of record on Tuesday, June 15th will be given a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 4.10%. The ex-dividend date of this dividend is Monday, June 14th. Gilead Sciences’s payout ratio is currently 40.06%.
A number of analysts recently issued reports on the stock. Sanford C. Bernstein upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $80.00 price target for the company in a research note on Thursday, April 1st. Redburn Partners raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating in a report on Tuesday, March 30th. SVB Leerink raised their target price on shares of Gilead Sciences from $72.00 to $74.00 and gave the stock an “outperform” rating in a report on Friday, April 30th. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “hold” rating and set a $69.00 price objective for the company in a research report on Wednesday, May 5th. Finally, Morgan Stanley increased their target price on Gilead Sciences from $81.00 to $83.00 and gave the stock an “overweight” rating in a research report on Monday, May 3rd. Ten analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $99.22.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.
Featured Story: What does EPS mean?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.